Roche to shed 170 jobs in diagnostics restructuring

Roche ($RHHBY) plans to cut 170 jobs in the U.S. and Germany as it winds down the applied sciences business in its lagging diagnostics division. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.